Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
FEATURED:
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
Fitzsimons Innovation Community is where innovators come to turn ideas into business.
A regular feature of a Fitzsimons Innovation Community visionary.
Our year in innovation.
Find out what’s happening on campus and across the industry.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Colorado Real Estate Journal's latest Health Care and Life Sciences Quarterly features an article from Dr. Terry Fry, Executive Director of the Gates Institute at University of Colorado Anschutz, about how the proximity between academia, biomanufacturing, and industry collaboration at Fitzsimons accelerates the development of life-changing cell and gene therapies.
Precision health and medicine giant Verily will be partnering with CU Anschutz and UCHealth to create an AI enabled ecosystem entailing research ready biomedical pipelines and datasets. In addition, the partnership is aiming to build curated AI models across a variety of specific therapeutic and drug areas, such as oncology, musculoskeletal and transplant medicine, to name a few. All of this work will be done using CU Anschutz’s vast research datasets via Verily Workbench, one of the company’s flagship products.
RheumaGen, Inc. and SiVEC Biotechnologies, Inc. today announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune diseases. The partnership will utilize SiVEC's BactPac™ drug delivery platform to streamline manufacturing and increase scalability of RheumaGen's new class of human leukocyte antigen (HLA) gene-editing therapies for common autoimmune diseases; importantly, the partnership also establishes an in vivo program that will be co-developed by the companies.
EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test® (EST), marking a major milestone in access for patients living with eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. The decision means that Medicare beneficiaries can now receive coverage for the EST, which provides a non-endoscopic, minimally invasive method to monitor esophageal inflammation. The test enables clinicians to track disease activity without the need for repeated sedated endoscopies, which are costly, burdensome, and carry procedural risks.
Change Please was named one of Instawork’s Community Partner of the Year winners for 2025. The Community Partner Awards recognized businesses prioritizing hiring from underserved local communities. With a Denver area location at Fitzsimons Innovation Community, the Change Please mission is to tackle homelessness through employment, training, and holistic support is transforming lives.
The Anschutz Foundation has committed up to $50 million to the University of Colorado Anschutz medical campus to jumpstart a sweeping new initiative in mental health. As a challenge gift, the investment aims to generate $200 million in funding from public and private partners and will create the CU Anschutz Campus Mental Health Collaborative to develop scalable, tech-enabled programs to improve access and interventions for adults and children in need of mental health care.
The city of Aurora is growing a reputation for helping developments get off the ground quickly by helping projects make it through the local permitting process without snags.
Onconaut Therapeutics, a privately-held therapeutics company and prior Innosphere client company, has received $2.5M in funding through a Fast-Track Small Business Technology Transfer (STTR) grant from the National Institute of Health, National Cancer Institute (NCI) for Onconaut to develop small molecule drug inhibitor targeting Chromodomain Helicase DNA binding protein (CHD1L), a novel oncogenic target for metastatic colorectal cancer and other cancers. The grant will allow Onconaut to rapidly develop a lead compound suitable for preclinical IND studies as a single agent and in combination with FOLFIRI.
Never Dream Alone, the latest phase of the CU Anschutz advertising campaign, filmed in collaboration with the Colorado Symphony at Boettcher Concert Hall. The music mirrors the process of discovery at CU Anschutz – a lone idea blossoming into new cures and treatments through innovation and collaboration. “This campaign is about our people, their ideas and the power of collaboration,” said Chancellor Don Elliman. “It is by thinking and dreaming big together that we drive advancements in health and medicine. We’re proud to have worked alongside another crown jewel of our state in the Colorado Symphony to create this one-of-a-kind piece.”
National Geographic spotlighted groundbreaking research led by CU Anschutz experts, uncovering how COVID-19 and the flu may awaken dormant cancer cells. This discovery raises important questions for survivor care and demonstrates how Colorado researchers are advancing knowledge that impacts lives worldwide.
Fitzsimons Innovation Community Chief Operating Officer Kenneth Ho on the set of AuroraNow discussing the newly approved Master Plan, and how Fitzsimons plans to soften the edges of the campus through internship programs with local schools, community art installations, and other initiatives.
Researchers from University of Colorado Anschutz Medical Campus and University of Colorado Boulder have developed a gecko-inspired material that clings to bladder cancer tumors and slowly releases chemotherapy, introducing a promising new approach that could reduce the need for repeat treatments.
Fitzsimons Innovation Community
